temozolomide has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 5.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| "Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma." | 3.75 | Non-Hodgkin lymphoma following temozolomide. ( Das, P; Dwary, A; Goyal, S; Gupta, D; Mohanti, BK; Muzumder, S; Sharma, A; Thulkar, S, 2009) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 1.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| "Temozolomide (TMZ) has established antineoplastic activity in the central nervous system in other disease states, with a favorable toxicity profile." | 1.51 | Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. ( Brenner, A; Butler, MJ; Faivre, G; Le, I, 2019) |
| "The temozolomide was stopped and the lymphoma was successfully treated with chemotherapy." | 1.38 | Non-Hodgkin's lymphoma in a patient on treatment with temozolomide. ( Otty, Z; Sabesan, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kaulen, LD | 1 |
| Baehring, JM | 1 |
| Wang, H | 1 |
| Wang, M | 1 |
| Wei, J | 1 |
| Wang, L | 1 |
| Mao, L | 1 |
| Jin, J | 1 |
| Zheng, J | 1 |
| Wang, C | 1 |
| Liu, F | 1 |
| Li, X | 1 |
| Xu, X | 1 |
| Chen, K | 1 |
| Wu, H | 1 |
| Wang, Y | 2 |
| Yang, S | 1 |
| Wang, K | 1 |
| Chen, C | 1 |
| Sun, P | 1 |
| Cui, J | 1 |
| Yan, S | 1 |
| Chen, H | 1 |
| Xia, Y | 1 |
| Bi, X | 1 |
| Liu, P | 1 |
| Yang, H | 1 |
| Nie, M | 1 |
| Zhang, XW | 1 |
| Jiang, W | 1 |
| Li, ZM | 1 |
| Batalini, F | 1 |
| Kaufmann, MR | 1 |
| Aleixo, GF | 1 |
| Drews, R | 1 |
| Faivre, G | 1 |
| Butler, MJ | 1 |
| Le, I | 1 |
| Brenner, A | 1 |
| Pulczynski, EJ | 1 |
| Kuittinen, O | 1 |
| Erlanson, M | 1 |
| Hagberg, H | 1 |
| Fosså, A | 1 |
| Eriksson, M | 1 |
| Nordstrøm, M | 1 |
| Østenstad, B | 1 |
| Fluge, Ø | 1 |
| Leppä, S | 1 |
| Fiirgaard, B | 1 |
| Bersvendsen, H | 1 |
| Fagerli, UM | 1 |
| Broes, K | 1 |
| Van Ginderachter, L | 1 |
| Joosens, E | 2 |
| Maes, A | 1 |
| Theunissen, K | 1 |
| Schepers, S | 1 |
| Deben, K | 1 |
| Claes, J | 1 |
| Mebis, J | 1 |
| Cox, T | 1 |
| Neyns, B | 1 |
| Cordera, S | 1 |
| Pouratian, N | 1 |
| Nader, P | 1 |
| Sharma, A | 1 |
| Gupta, D | 1 |
| Mohanti, BK | 1 |
| Thulkar, S | 1 |
| Dwary, A | 1 |
| Goyal, S | 1 |
| Muzumder, S | 1 |
| Das, P | 1 |
| Otty, Z | 1 |
| Sabesan, S | 1 |
| Osmani, AH | 1 |
| Masood, N | 1 |
| Herrlinger, U | 1 |
| Hebart, H | 1 |
| Kanz, L | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Woll, PJ | 1 |
| Crowther, D | 1 |
| Johnson, PW | 1 |
| Soukop, M | 1 |
| Harper, PG | 1 |
| Harris, M | 1 |
| Brampton, MH | 1 |
| Newlands, ES | 1 |
| Reni, M | 1 |
| Ferreri, AJ | 1 |
| Landoni, C | 1 |
| Villa, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomi[NCT01458730] | Phase 2 | 66 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
1 review available for temozolomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
2 trials available for temozolomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2015 |
Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle | 1995 |
13 other studies available for temozolomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child | 2018 |
Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Central Nervous System Neoplasms; Combined Modalit | 2018 |
miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; DNA Modification Methylases; DN | 2020 |
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Femal | 2019 |
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Topics: Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Fata | 2019 |
Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Disea | 2019 |
Secondary non-Hodgkin lymphoma of the ethmoid sinus after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Ethmoid Sinus; Humans; Lymphoma, Non-Hodgkin; Male; | 2015 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2008 |
Non-Hodgkin lymphoma following temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, Non-H | 2009 |
Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Chemoradiotherapy; Dacarbazine; Gliob | 2012 |
Temozolomide for relapsed primary CNS lymphoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Ne | 2012 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo | 2005 |
Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Immunocompetence; Lym | 2000 |